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OBJECTIVE—In severely obese individuals and patients with
diabetes, accumulation and activation of macrophages in adipose
tissue has been implicated in the development of obesity-
associated complications, including insulin resistance. We
sought to determine whether in a healthy population, adiposity,
sex, age, or insulin action is associated with adipose tissue
macrophage content (ATMc) and/or markers of macrophage
activation.
RESEARCH DESIGN AND METHODS—Subcutaneous ATMc
from young adult Pima Indians with a wide range of adiposity
(13–46% body fat, by whole-body dual-energy X-ray absorptiom-
etry) and insulin action (glucose disposal rate 1.6–9 mg/kg
estimated metabolic body size/min, by glucose clamp) were
measured. We also measured expression in adipose tissue of
factors implicated in macrophage recruitment and activation to
determine any association with ATMc and insulin action.
RESULTS—ATMc, as assessed by immunohistochemistry
(Mphi) and by macrophage-speciﬁc gene expression (CD68,
CD11b, and CSF1R), were correlated with percent body fat, age,
and female sex. Gene expression of CD68, CD11b, and CSF1R
but not Mphi was correlated negatively with glucose disposal
rate but not after adjustment for percent body fat, age, and sex.
However, adipose tissue expression of plasminogen activator
inhibitor type-1 (PAI-1) and CD11 antigen-like family member C
(CD11c), markers produced by macrophages, were negatively
correlated with adjusted glucose disposal rate (r  0.28, P 
0.05 and r  0.31, P  0.03).
CONCLUSIONS—ATMc is correlated with age and adiposity
but not with insulin action independent of adiposity in healthy
human subjects. However, PAI-1 and CD11c expression are
independent predictors of insulin action, indicating a possible
role for adipose tissue macrophage activation. Diabetes 58:
385–393, 2009
O
besity is an inﬂammatory condition leading to
chronic activation of an innate immune re-
sponse (1). This inﬂammatory response has
been implicated in the pathogenesis of obesity-
associated complications, including atherosclerosis (2),
nonalcoholic fatty liver disease (3), and insulin resistance
(4). Adipose tissue is a primary site of obesity-induced
inﬂammation and a complex organ containing adipocytes
as well as connective tissue matrix, nerve tissue, stromal
vascular cells, and immune cells. A cardinal feature of
obesity-induced inﬂammation in adipose tissue is the
recruitment of immune cells, speciﬁcally macrophages
(5,6). Although the adipocyte is the deﬁning cell of adipose
tissue and does contribute to the production of inﬂamma-
tory molecules (7), it appears that macrophages contribute
substantially to the inﬂammatory signals that are induced
by obesity (5,8–11).
Among the inﬂammatory factors whose expression is
upregulated in adipose tissue with the onset of obesity,
some have been implicated in recruitment of macrophages
to adipose tissue, including chemokines, while others
appear to be derived primarily from adipose tissue mac-
rophages (ATMs). Studies in rodents indicate that ATMs
are bone marrow–derived cells recruited to adipose tissue
during periods of positive energy balance and increasing
adiposity (5). However, the physiology of macrophage
recruitment remains largely unknown. It has been hy-
pothesized that a metabolic signal(s) or stress(es) leads
to activation of endothelial cells, production of che-
moattractants with subsequent transendothelial migra-
tion of monocytes (12), monocyte differentiation into
mature macrophages, and ultimately macrophage activa-
tion. A few studies have also suggested that differentiation
of adipocyte precursors into macrophage-like cells (6,13)
can occur, although this remains controversial. Studies
have implicated monocyte chemoattractant proteins, hyp-
oxia, and angiogenesis in ATM recruitment. In particular,
the adhesion molecule intercellular adhesion molecule 1
(ICAM1) is important in the recruitment of monocytes to
sites of inﬂammation (14), its soluble plasma concentra-
tions have been found to be positively associated with
adiposity (15,16), and in previous microarray studies in
mice adipose tissue Icam1 expression was correlated with
body mass (5).
Animal and human studies of obese and diabetic sub-
jects indicate that adipose tissue macrophage content
(ATMc) correlates with degree of adiposity (5,6,8,9,12). In
a small, interventional study, the subcutaneous expression
of CD68, a macrophage marker, correlated with insulin
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DIABETES, VOL. 58, FEBRUARY 2009 385resistance (10). In obese individuals, the degree of hepatic
ﬁbroinﬂammatory lesions or fat liver content is associated
with omental or subcutaneous ATM inﬁltration (17–19).
The association of ATMc with insulin resistance and
nonalcoholic fatty liver disease indicates a role for ATMc
in obesity-related complications. However, it is not clear
yet whether ATMc or activation in healthy adults affects
insulin action beyond their association with adiposity. In
rodents, genetic manipulation of the activation of myeloid
cells, including macrophages, alters insulin sensitivity
(20–22).
In the present study, we examined in healthy nondia-
betic individuals the association of subcutaneous ATMc
and activation with direct measurements of both adiposity
and whole-body insulin sensitivity. In addition, we inves-
tigated the relationship of ATMc and subcutaneous adi-
pose tissue expression of genes potentially involved in
attraction of macrophages into adipose tissue.
RESEARCH DESIGN AND METHODS
Adult Native Americans (at least one-half Pima or closely related Tohono
O’odham Indians) participated in an ongoing longitudinal study to identify risk
factors for type 2 diabetes and obesity. All subjects were nondiabetic, did not
smoke or take medications at the time of the study, and were in good health,
as determined by medical history, physical examination, and routine labora-
tory testing. Based on our database of previously studied volunteers, subjects
were selected who had frozen subcutaneous adipose tissue in our tissue bank
and measurements of both percent body fat and insulin action. For the study
protocol, subjects were admitted to the Clinical Research Unit of the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Phoenix,
AZ) for 8–15 days and were provided a standard weight-maintaining diet
containing 50% of calories as carbohydrate, 30% as fat, and 20% as protein for
at least 3 days before metabolic testing. The NIDDK Institutional Review
Board and the Gila River Indian Tribal Council approved the study. Before
participation, written informed consent was obtained.
Height was measured using a stadiometer; weight was obtained from an
electronic digital scale. Percentage of body fat was measured by whole-body
dual-energy X-ray absorptiometry. Glucose tolerance status was assessed by a
75-g oral glucose tolerance test (23). Insulin action was assessed at physio-
logical insulin concentrations using a hyperinsulinemic-euglycemic glucose
clamp (24). The mean steady-state insulin concentration during the clamps
was 148  37 pmol/l. The rate of total insulin-stimulated glucose disposal (M)
was calculated for the last 40 min of insulin infusion and adjusted to
steady-state glucose and insulin concentrations. All measurements derived
from the glucose clamp were expressed per kilogram estimated metabolic
body size (fat-free mass  17.7 kg) (25). Plasma insulin concentrations were
measured by two different radioimmunoassays used over time in our lab:
Concept 4 (ICN, Costa Mesa, CA) and Access (Beckman Instruments).
Insulin assays. All measurements of insulin were normalized to original
radioimmunoassay (a modiﬁed Herbert-Lau assay) using regression equations.
Fat biopsy, morphological analysis, and real-time quantitative PCR.
After an overnight fast, subcutaneous adipose tissue is obtained by percuta-
neous needle biopsy of periumbilical fat depots using a 15-gauge needle
through skin and anesthetized with 1% lidocaine. These tissue samples are
immediately frozen in liquid nitrogen for subsequent studies, such as the one
herein presented. Adipose tissue samples were ﬁxed for 12–16 h at room
temperature in zinc-formalin ﬁxative (Anatech, Battle Creek, MI) and embed-
ded in parafﬁn. Five-micrometer sections, cut at 50-m intervals, were
mounted on charged glass slides, deparafﬁnized in xylene, and stained for
expression of CD68 as done previously (Caltag, Burlingame, CA) (5). For each
individual tissue block, four different 20 ﬁelds from each of ﬁve different
sections were analyzed independently by two blinded evaluators. The total
number of nuclei and the number of nuclei of CD68-expressing cells were
counted for each ﬁeld. The fraction of macrophage cells for each sample was
calculated as the number of nuclei of CD68-expressing cells divided by the
total number of nuclei in sections of the sample.
Total RNA was extracted from frozen adipose tissue (50 mg) using a
commercially available acid-phenol reagent (Trizol; Invitrogen, Carlsbad, CA).
First-strand cDNA was synthesized using Superscript III reverse transcriptase
and random hexamer primers as described in the manufacturer’s protocol
(Invitrogen). Samples of cDNA were diluted 1:25 in nuclease-free water
(Qiagen, Valencia, CA). PCR ampliﬁcation mixtures (20 l) contained 10 l2 
PCR SYBR Green I Quantitect Master mix (Qiagen), 0.4 l2 5mol/l reverse
and forward primer mix, and 11.6 l diluted cDNA template. Real-time
quantitative PCR was carried out using the DNA Engine Opticon (MJ
Research, Waltham, MA) instruments with the following cycling parameters:
polymerase activation, 15 min, 95°C; ampliﬁcation for 40 cycles, 15 s, 94°C;
20 s, 58°C; 20 s, 72°C. After ampliﬁcation, melting curve analysis was
performed as described in the manufacturers’ protocol (Qiagen). The control
gene, casein kinase-1d (CSNK1d), was used to normalize simple load and
reactions and for calculation of -Ct values, from which relative expression
values were determined (arbitrary units [AU]). Human primer orientation and
sequences were as follows: CSNK1d forward, 5	-AGGAGAAGAGGTTGCCAT
CAAG-3	, and reverse, 5	-TCCATCACCATGACGTTGTAGTC-3	; CD68 for-
ward, 5	-GCTACATGGCGGTGGAGTACAA-3	, and reverse, 5	-ATGATGAGAG
GCAGCAAGATGG-3	; integrin 
M (ITGAM)/CD11b forward, 5	-GAGTCCAAC
GCTAATGTCAAGG-3	, and reverse, 5	-CCCGTAGAGAACAGCATCACAC-3	;
CSF1R forward, 5	-GCTCAACCTCAAAGTCATGGTG-3	, and reverse, 5	-GAA
GGTGTGCCTGTATGTGTCC-3	; LEP/Leptin forward, 5	-TGGCCCTATCTTTT
CTATGTCC-3	, and reverse, 5	-GGTGACTTTCTGTTTGGAGGAG-3	; ICAM1
forward, 5	-CAGTCACCTATGGCAACGACTC-3	, and reverse, 5	-GCCTCACA
CTTCACTGTCACCT-3	; CCL-2/MCP-1 forward, 5	-CAATCAATGCCCCAGTCA
CC-3	, and reverse, 5	-GAATCCTGAACCCACTTCTGC-3	; plasminogen
activator inhibitor type-1 (PAI-1) forward, 5	-CTGGTTCTGCCCAAGTTCTCC,
and reverse 5	-CCACAAAGAGGAAGGGTCTGTC; hypoxia-inducible factor-1

(HIF-1a) forward, 5	-AGAACAAAACACACAGCGAAGC, and reverse, 5	-AATC
AGCACCAAGCAGGTCATA-3	; vascular endothelial growth factor (VEGF)
forward, 5	-AGCCTTGCCTTGCTGCTCTAC-3	, and reverse, 5	-ACCACTTCGT
GATGATTCTGC-3	; C1QB forward, 5	-ACTGATGTTGCTCCTGCTCCTG-3	,
and reverse, 5	-GGTCTCCCTTCTCTCCGAACTC-3	; S100A8 forward, 5	-GGC
AAGTCCGTGGGCATC-3	, and reverse, 5	-ATCCAACTCTTTGAACCAGACG-
3	; tumor necrosis factor (TNF) forward, 5	-TGCTTGTTCCTCAGCCTCTTC-3	,
and reverse, 5	-GCTTGTCACTCGGGGTTCG-3	; matrix metalloproteinase-9
(MMP9) forward, 5	-ACCTTCTTGGCTACCTTTGACG-3	, and reverse, 5	-ATG
GCTTTCCTTCTCCTCAGAC-3	; and CD11c forward, 5	-CAGAGATGCGTGGA
GAGTCG-3	, and reverse, 5	-GACACCAAACTGGATGACGATG-3	.
Statistical analysis. Statistical analyses were performed using SAS software
(SAS version 9.1; SAS Institute, Cary, NC). Non–normally distributed variables
were log transformed (log10) to reduce skewness, and then normality was
reevaluated. Unadjusted sex differences in variables under investigation were
evaluated by Student’s t tests or nonparametric (Kruskall-Wallis) test. Pearson
or Spearman correlation analysis was used to quantify relationships between
variables of interest before and after (partial correlations) adjustment for
covariates. General linear regression models (GLMs) adjusted for age and
body fat were used to investigate sex differences in variables of interest and
to test for interaction terms. GLMs were used to test for nonlinear associa-
tions between ATMc and age both before and after adjusting for covariates. In
these models, age was included as a quadratic term. Level of statistical
signiﬁcance was set at P  0.05.
RESULTS
Anthropometric and metabolic characteristics and
ATMc. Men were taller and heavier and had lower body
fat than women. Women had higher 2-h plasma glucose
concentrations than men. No differences between sexes in
M were observed both before (P  0.2) and after adjust-
ment for age and body fat (P  0.5). ATMc was assessed
by immunohistochemical (IHC) analysis (Mphi) and gene
expression of macrophage-speciﬁc genes (CD68, CSF1R,
and CD11b or ITGAM). As previously reported, we found a
higher expression of macrophage content in adipose tissue
of women compared with men, which was statistically
signiﬁcant for CSF1R and CD11b (Table 1). However, after
adjusting for adiposity, there were no sex-dependent dif-
ferences in these markers (P  0.7 and 0.3 for CSF1R and
CD11b, respectively).
Measures of ATMc and their association with adipos-
ity and age. No single measurement fully captures the
heterogeneous ATMc of an adipose tissue sample. IHC
analysis visually identiﬁes cells but depends on the expres-
sion of a single protein or antigen, and given the hetero-
geneity of macrophage population in adipose tissue, no
single antigen is likely to be expressed above the threshold
of detection on all macrophages. Furthermore, ATMc is
not uniform, and therefore, variations in macrophage
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macrophage content in a given sample. The increase in
ATMc was originally discovered when it was noted that
the expression of macrophage-speciﬁc genes was corre-
lated with adiposity in mice. Recognizing the limits of both
approaches, we studied ATMc as assessed by IHC (frac-
tion of CD68-expressing cells, Mphi) and gene expression
of macrophage-speciﬁc genes. Mphi was correlated with
gene expression of CD68 (r  0.58, P  0.0001), CSF1R
(r  0.46, P  0.001), and CD11b (r  0.43, P  0.003).
CD68 expression was correlated with CSF1R (r  0.68)
and CD11b (r  0.62), and CSF1R and CD11b were
correlated with each other (r  0.75) (all P  0.0001).
These correlations suggest that each approach measures
related and overlapping aspects of macrophage content,
but none captures it entirely.
In this healthy population of young adults, subcutane-
ous ATMc as assessed by Mphi and macrophage gene
expression was positively associated with body fat (shown
in Fig. 1). ATMc was also associated with BMI (r  0.36,
P  0.02, for Mphi; and r  0.34, r  0.45, r  0.49, all P 
0.01, for CD68, CSF1R, and CD11b expression, respec-
tively). This relationship between adiposity and ATMc did
not differ by sex (P  0.3 for both sex  body fat and
sex  BMI interaction terms). Leptin expression, as a local
measurement of adiposity, was also associated with Mphi
(r  0.30, P  0.04) and expression of macrophage
markers (CD68: r  0.26, P  0.03; CSF1R: r  0.23, P 
0.06; CD11b: r  0.37, P  0.002).
No association was found between age and percent
body fat (P  0.8). However, as depicted in Fig. 2, ATMc
increased with advancing age until 31–33 years and then
slightly decreased. Hence, a linear regression model of the
relation between ATMc and age, including quadratic terms
(age





n 66 41 25
Age (years) 31  83 1  93 1  6
Body weight (kg) 95  22 99  21* 89  23
Height (cm) 167  7 172  6† 161  4
BMI (kg/m
2) 34  73 4  73 5  8
Body fat (%) 32  72 9  6† 38  6
Fasting glucose (mg/dl) 88  98 7  88 9  11
2-h glucose (mg/dl) 118  29 112  29‡ 129  28




1)§ 2.9  1.2 3  1.4 2.6  0.8
Mphi (%)¶ 27  12 25  11 30  11
CD68 (AU) 1.07  1.04 1  1.15 1.18  0.84
CSF1R (AU) 1.76  1.73 1.3  1.07† 2.52  2.3
CD11b (AU) 0.09  0.06 0.08  0.06‡ 0.1  0.06
Leptin (AU) 34  28 25  20† 48  33
Data are means  SD. *P  0.08, †P  0.01, or ‡P  0.05 for t test or
Wilcoxon comparisons across groups. §M was only available in 65
(of 66) subjects (24 women). ¶Mphi was available only in 46 (of 66)
(men/women: 31/15) individuals in which adipose tissue section, cell
morphology, and staining met the required criteria. 2-h glucose, 2-h
glucose after a 75-g glucose load; EMBS, estimated metabolic body
size. AU, adipose tissue mRNA values were normalized using mRNA
expression of csnk1d. CD68 (macrophage-myeloid–associated anti-
gen), CSF1R (colony-stimulating factor-1 receptor), and CD11b
(ITGAM).
FIG. 1. Associations of adiposity with fraction of CD68
 cells (A) and mRNA expression of macrophage markers (B, CD68 expression [AU, ln];
C, CSF1R expression; D, CD11b expression). Simple correlation coefﬁcients and P values for associations are given. U, men; F, women. Fraction
of CD68
 cells was available in 46 individuals (31 men and 15 women) in whom adipose tissue section, cell morphology, and staining met the
required criteria. AU, mRNA values were normalized using mRNA expression of csnk1d.
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signiﬁcant for all of the ATMc variables. Equations yielded
by these models were as follows: Mphi (fraction of CD68

cells)  0.6  0.06  age  0.001  age
2; CD68
expression (AU, ln)  5.6  0.34  age  0.01  age
2;
CSF1R expression (AU, ln)  5.5  0.36  age  0.01 
age
2; CD11b expression (AU, ln)  8.8  0.39  age 
0.01  age
2.
Thus, in healthy, relatively young adults, macrophage
content in a subcutaneous depot correlated with direct
and indirect measures of adiposity and age independently.
However, the fact that some of the macrophage markers
were higher in women than men was dependent on
differences in adiposity.
Association of ATMc with insulin action. As expected,
body fat was negatively associated with M (r  0.34, P 
0.006); a trend for an association between age and M was
also noted (r  0.23, P  0.07). There was no association
between Mphi and M (Fig. 3). Expression of CD68, CSF1R,
and CD11b was negatively associated with M (Fig. 3).
However, after adjustment for age and body fat, the
negative correlation between macrophage gene expres-
sion and M was no longer signiﬁcant (all P  0.4). This
relationship did not differ by sex (P  0.2 for sex  ATMc
[Mphi or markers] interaction terms in these models).
These data argue that any systemic metabolic effect of
subcutaneous ATMc that may exist cannot be separated
from the dominant effects of adiposity.
Relationship between ATMc and inﬂammatory mark-
ers. We next studied the relationship between ATMc and
the expression of inﬂammatory markers, including those
implicated in recruitment and activation of macrophages.
For this endeavor, only data from 56 individuals could be
analyzed because of missing data for all of the inﬂamma-
tory markers we measured or lack of enough adipose
tissue to measure them in every subject from our initial
study group (n  66). We found that expression of ICAM1
was associated with percent body fat (r  0.33, P  0.01).
Consistent with our murine data and a potential role for
Icam1 in ATM recruitment, expression of ICAM1 was also
associated with ATMc as assessed by macrophage gene
expression. The association of ATMc and ICAM1 expres-
sion is markedly attenuated when adjusted for percent
body fat (P  0.03, 0.08, and 0.12, for CD68, CSF1R, and
CD11b expression, respectively), suggesting that any role
of ICAM1 in ATM accumulation is not independent of
adiposity (Table 2).
Chemokine monocyte chemoattractant protein-1 CCL-2
(also known as MCP-1) is a chemokine whose circulating
blood concentrations are elevated in obese humans
(26,27) and rodents (28) and whose expression is in-
creased in adipose tissue of obese mice (28). In this study,
CCL-2 expression correlates with body fat (r  0.29, P 
0.03) and is also correlated with macrophage content,
consistent with its role as chemoattractant for monocytes
and macrophages. After adjustment for percentage of
body fat, CCL-2 is still associated with CD68, CSF1R, and
CD11b expression (all P  0.05) but not with IHC-
measured macrophage content (P  0.2).
Macrophage migration inhibitory factor (MIF) is pro-
duced by both human mature adipocytes (29) and macro-
phages (30), is closely related with BMI (30), and is
positively associated with insulin action (31). However, we
FIG. 2. Associations of age with fraction of CD68
 cells (A) and mRNA expression of macrophage markers (B, CD68 expression [AU, ln]; C, CSF1R
expression; D, CD11b expression). Total r
2 and P values for the entire GLM are given. Models were built using linear and quadratic terms
(macrophage content variable  age age
2). U, men; F, women. Fraction of CD68
 cells was available in 46 individuals (31 men and 15 women)
in whom adipose tissue section, cell morphology, and staining met the required criteria. AU, mRNA values were normalized using mRNA
expression of csnk1d.
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MIF expression and ATMc.
Adipocyte hypertrophy-associated hypoxia has been
proposed to induce signals that recruit and retain macro-
phages in adipose tissue. HIF-1a is a master regulator of
hypoxia-induced transcription and responses. Contrary to
our predictions, expression in adipose tissue of HIF-1a and
one of its downstream target genes, i.e., VEGF, correlate
negatively with measures of macrophage content. No sex
differences in adipose tissue expression of any of these
genes were found before or after adjustment for age and
body fat.
Adipose tissue macrophage activation relationship
with fasting insulin and insulin action. Obesity not
only increases ATMc but also increase macrophage inﬂam-
matory gene expression. We selected four inﬂammatory
genes (TNF-
, PAI-1, complement factor C1qb [C1QB],
and the Ca
2-binding neutrophil cytosolic protein
[S100a8]) that have been shown to be correlated with body
mass and fasting plasma insulin concentrations and are
substantially produced by ATMs in both animals (5) and
humans (11). Expression of TNF-
 and PAI-1 have previ-
ously been implicated in obesity-induced complications,
and these factors are expressed by macrophages within
the adipose tissue (5,11). C1QB is part of the classical
complement system mostly expressed in the stroma frac-
tion of the adipose tissue (32), and S100a8 is involved in
immune and inﬂammatory processes (33). We also mea-
sured CD11 antigen-like family member C (CD11c), a
marker of macrophage polarization toward a classically
(proinﬂammatory) activated state (34), and MMP9, which
is produced and secreted by activated ATMs (35). C1QB
(r  0.33, P  0.01), TNF-
 (r  0.51, P  0.001), S100a8
(r  0.30, P  0.02), CD11c (r  0.36, P  0.007), and
MMP9 (r  0.43, P  0.001) expression, but not PAI-1,
were associated with body fat. CD11c and MMP9 were
also associated with age (r  0.38 and 0.43, both P  0.01).
Sex differences were found for TNF-
, MMP9, and CD11c
expression; however, these differences disappeared (all
P  0.3) after accounting for the differences in adiposity
between sexes. TNF-
, PAI-1, MMP9, and CD11c were
associated with both fasting insulin (r  0.37, 0.37, 0.29,
and 0.30, respectively, all P  0.05) and M (Fig. 4; r 
0.24, P  0.08; r  0.29, P  0.03; r  0.40, P  0.01;
and r  0.40, P  0.01, respectively) and C1QB and
S100a8 with fasting insulin (r  0.27, P  0.05; and r 
0.23, P  0.09, respectively). After adjustment for percent
body fat, the correlations of C1QB, TNF-
, and S100a8
with M or fasting insulin were no longer signiﬁcant.
However, after adjustment for age, sex, and percent body
fat, the association between MMP9 and CD11c with fasting
insulin was no longer signiﬁcant (P  0.3 and 0.09,
respectively), and the association with M was attenuated
although still signiﬁcant for CD11c (r  0.25, P  0.08;
and r  0.31, P  0.03, respectively). After adjustment
for age, sex, and percent body fat, PAI-1 expression was
still negatively correlated with M (r  0.28, P  0.05) and
FIG. 3. Associations between insulin-stimulated glucose uptake and ATM content. Simple correlation coefﬁcients and P values for associations
are given. U, men; F, women. Fraction of CD68
 cells was available in 46 individuals (31 men and 15 women) in whom adipose tissue section, cell
morphology, and staining met the required criteria. EMBS, estimated metabolic body size. AU, mRNA values were normalized using mRNA
expression of csnk1d.
TABLE 2
Associations between potential macrophage attractors and ATM
content
Mphi* CD68 CSF1R CD11b
CCL-2 0.32, 0.05 0.39, 0.003 0.39, 0.003 0.51, 0.001
ICAM 0.19, 0.3 0.39, 0.003 0.37, 0.005 0.34, 0.01
MIF 0.21, 0.2 0.05, 0.7 0.01, 0.9 0.15, 0.3
HIF-1 0.40, 0.01 0.23, 0.09 0.21, 0.12 0.12, 0.4
VEGF 0.39, 0.02 0.26, 0.05 0.25, 0.07 0.30, 0.02
Data are Spearman’s correlation coefﬁcients and P values for asso-
ciations in 56 individuals. *n  38 (men/women: 27/11) for correla-
tions with Mphi.
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0.01).
DISCUSSION
In healthy, young subjects, adipose tissue macrophage
content was associated with adiposity, adipose tissue
leptin expression, and age but not with whole-body insu-
lin–mediated glucose disposal after adjusting for adipos-
ity. However, expression in adipose tissue of PAI-1, MMP9,
and CD11c, putative markers of macrophage activation,
was associated with whole-body insulin action. After ad-
justment for confounders, HIF1a and VEGF were nega-
tively associated with subcutaneous adipose tissue
macrophage content, as assessed by IHC analysis, and
CCL-2 expression was positively associated with gene
expression of macrophage markers (CD68, CSF1R, and
CD11b). Expression of ICAM was associated with ATMc;
however, this relationship was markedly attenuated after
accounting for adiposity.
Subcutaneous and visceral ATMc increases with degree
of adiposity (5,6,8,9,12,36,37), particularly intra-abdominal
fat mass (37), and may have ethnic and metabolic deter-
minants (37). Weight loss, either after bariatric surgery (8)
or after diet and exercise (36), reduces adipose tissue
macrophage content. Most (8,10,17,37), but not all (9), of
previous human studies investigating this association have
mainly studied Caucasian women. In this study, healthy
male and female Pima Indians with a wide range of
adiposity were included. No sex differences in ATMc were
found when adiposity was accounted for, and no sex
differences were observed for the association between
adiposity and ATMc in agreement with a previous study
(9). Subcutaneous ATMc was also positively associated
with age in our population of young adults (18–44 years).
These data indicate that at a certain age (31–33 years in
our population), ATMc reaches a plateau, after which
ATMc may decrease. Whether this is because of an issue of
population selection (Pima Indians who develop diabetes
at a young age would not be included, and so relatively
lower-risk individuals would have been studied) cannot be
determined. Associations of age and ATMc were described
in studies of leptin-deﬁcient (Lepob/ob) mice in which
clusters of macrophages were more prevalent as the obese
mice aged (6) and in humans populations in which age was
positively correlated with both subcutaneous (8,37) and
omental (17,37) adipose tissue macrophage content.
Hence, ATM accumulation is a common feature of increas-
ing age and adiposity independent of sex, ethnicity, adi-
pose tissue depot, and diagnosis of diabetes.
A number of in vitro and animals studies have impli-
cated ATM recruitment and activation in the development
of adverse metabolic consequences of obesity, in par-
ticular insulin resistance. Incubation of adipocytes in
macrophage-conditioned medium activates an inﬂam-
matory and lipolytic transcriptional program (38,39) and
decreases insulin-stimulated glucose uptake (38,40).
Myeloid-speciﬁc deletion of I
B kinase  (20) reduces
macrophage inﬂammation and protects from the detri-
mental effect of a high-fat diet on systemic insulin
action, and conversely, myeloid-speciﬁc deletion of per-
oxisome proliferator–activated receptor  increases the
inﬂammatory proﬁle of macrophages and reduces insu-
lin sensitivity (21,22). An increase in adipose tissue
expression of macrophage markers precedes the in-
crease in fasting insulin in mice fed a high-fat diet
during the development of obesity (6). Mice lacking the
C-C motif chemokine receptor-2 (CCR-2) or Cbl-associ-
ated protein (Cap), which are both involved in migration
of monocyte/macrophage cells, have lower macrophage
content in adipose tissue and are partially protected
from insulin resistance (41,42). Transgenic mice over-
expressing CCL-2/MCP-1 showed increased macrophage
accumulation in adipose tissue and were more insulin
resistant than wild-type littermates (28,43).
Although these in vitro and animal studies indicate that
adipose tissue macrophages may affect insulin action,
evidence in humans is scarce. In obese subjects, omental
ATMc was associated with severity of hepatic ﬁbroinﬂam-
matory lesions but not with fasting insulin or the quanti-
tative insulin sensitivity check index (QUICKI) after
accounting for sex (17). Similar lack of association with
insulin resistance was reported for subcutaneous ATMc in
obese individuals undergoing bariatric surgery in whom
changes (reduction) in inﬁltrating macrophages after
weight loss were associated with changes in plasma levels
of acute-phase proteins (serum amyloid and orosomucoid)
but not with changes in fasting insulin or QUICKI (8). An
association between insulin action (as measured by a
tolbutamide-modiﬁed frequently sampled intravenous glu-
cose tolerance test) and subcutaneous CD68 gene expres-
sion was found in 18 subjects, largely women, with normal
glucose tolerance (10). However, this association was not
adjusted for adiposity, a major confounder of this associ-
FIG. 4. Associations of adipose tissue expression of PAI-1, MMP9, and
CD11c with insulin-mediated glucose uptake. Data are simple Spear-
man’s correlation coefﬁcients and P values for associations in 55
individuals (M was missed for one of the subjects). U, men; F, women.
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using indirect methods. In the present study, using the
euglycemic-hyperinsulinemic clamp technique, insulin ac-
tion was weakly correlated with macrophage-speciﬁc gene
expression (but not macrophage content as measured by
IHC), but this association was no longer signiﬁcant after
adjustment for adiposity. It is possible that macrophage
accumulation in other adipose depots, in particular in the
visceral depot, may be associated with insulin action.
However, a recent study reporting higher levels of macro-
phages in visceral compared with subcutaneous adipose
tissue showed that the associations found between ATM
counts and clinical parameters of obesity and its comorbid
manifestations (including BMI, waist circumference, blood
pressure, and fasting insulin) were of similar magnitude
for both visceral and subcutaneous depots (37). In this
study, we did not measure ATMc in visceral adipose tissue,
but even assuming greater ATMc in visceral compared
with subcutaneous adipose tissue, we do not know
whether this would have also implied differences in the
associations herein reported.
Macrophage activation, rather than number, may be
more important in mediating the association between
inﬂammation and lower insulin-mediated glucose uptake.
TNF-
 (a pleiotropic cytokine), PAI-1, S100a8 (33), C1QB
(44), and MMP9 (45) are all proteins expressed at low
levels in resting macrophages and upregulated by activa-
tion. Adipose tissue macrophages expressing the CD11c
receptor are in a proinﬂammatory state (34), and activated
ATMs produce and secrete MMP9 proportionally to the
degree of adiposity (7,35,45). We found adipose tissue
expression of TNF-
, S100a8, C1QB, CD11c, and MMP9 to
be associated with adiposity in agreement with the hypoth-
esis of obesity being an inﬂammatory condition. Further-
more, gene expression of PAI-1, MMP9, and CD11c was
negatively associated with whole-body insulin sensitivity.
The association between MMP9 was attenuated after
adjusting for confounders. However, the association of
CD11c and insulin action was still signiﬁcant. PAI-1 was
initially identiﬁed as an inhibitor to ﬁbrinolysis but has
inﬂammatory and metabolic function beyond its role in
coagulation homeostasis. Insulin sensitivity is enhanced in
PAI-1
/ mice on a high-fat diet compared with wild-type
littermates (46). In humans, plasma PAI-1 activity is also
negatively and independently associated with insulin sen-
sitivity (47), and elevated baseline concentrations predict
development of type 2 diabetes (48). It is important to
acknowledge that within the adipose tissue, nonadipocyte
cells, rather than adipocytes, are the primary source of
PAI-1 (49,50) and that when irradiated PAI-1
/ mice are
reconstituted with bone marrow from PAI-1–deﬁcient
mice, PAI-1 expression decreases by 66% (51). Taken
together with our results, we can speculate that PAI-1 and
other factors produced from activated adipose tissue
macrophages might inﬂuence whole-body insulin action.
In fact, another group has also reported that PAI-1 mRNA
expression in abdominal subcutaneous adipose tissue is
positively related with insulin resistance (52).
The molecular mechanisms responsible for ATM recruit-
ment remain unknown. It has been reported that macro-
phage accumulation plays a major role in angiogenesis
(53). Adipose tissue expansion, like tumors, is angiogene-
sis dependent (54). A hypoxic/vascular theory proposes
that adipocytes may become hypoxic during a rapid ex-
pansion of adipose tissue and start secreting inﬂammatory
cytokines (to increase blood ﬂow) and angiogenic factors
to promote formation of new blood vessels (55,56). Both
leptin and CCL-2, whose expression in adipose tissue
increases with adiposity, have angiogenic properties
(57,58) and have been implicated in the recruitment of
macrophages to adipose tissue (12,28,42,43). In this study,
leptin and CCL-2 expression were positively related to
ATMc. HIF-1 orchestrates the cellular responses to hyp-
oxia. On activation, HIF-1a translocates to the nucleus and
induces transcription of downstream target genes, such as
VEGF, which is involved in angiogenesis. HIF-1 and VEGF
are highly expressed by macrophages (59,60). VEGF is
involved in angiogenesis during fat tissue formation
(61,62), and this effect might be mediated by macrophages
(63). In this study, expression of both HIF and VEGF
mRNA was negatively associated with macrophage con-
tent. This negative association could represent adipose
tissue failure to increase its vascularization in an attempt
to limit further weight gain. However, this cannot be
veriﬁed in this cross-sectional study.
Finally, we acknowledge that part of the interpretations
of the results in this and other previous studies are based
on correlations between gene expression data. Because of
methodological issues (e.g., possible different ampliﬁca-
tion efﬁciency of samples), such correlations may overes-
timate (or rarely underestimate) true associations,
although the fact that several ATM activation markers
point to the same direction points to the reliability of the
results.
In summary, our data indicate that aging and increasing
adiposity are associated with adipose tissue macrophage
inﬁltration. However, we found no independent associa-
tion between subcutaneous ATMc and directly measured
insulin action, indicating that ATMc per se is not a direct
cause of insulin resistance. However, consistent with
studies in mice, the expression of the macrophage activa-
tion marker PAI-1 was associated with insulin resistance,
as was CD11c independent of adiposity. These data are
consistent with a model in which macrophage activation
rather than content is related to insulin action and
suggest that further characterization of ATM popula-
tions and activation states may provide insights into the
relationship between obesity-induced inﬂammation and
insulin sensitivity.
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